Study of Standard Systemic Therapy in Treating Prostate Cancer

Clinical Trial Title

Phase III randomized trial of standard systemic therapy (SST) versus standard systemic therapy plus definitive treatment (surgery or radiation) of the primary tumor in metastatic prostate cancer.

Contact Information

Rush Cancer Center Clinical Trials Office

Clinical Trial Protocol Description:

This phase III trial studies how well standard systemic therapy with or without definitive treatment (prostate removal surgery or radiation therapy) works in treating participants with prostate cancer that has spread to other places in the body. Addition of prostate removal surgery or radiation therapy to standard systemic therapy for prostate cancer may lower the chance of the cancer growing or spreading.

Clinical Trial Eligibility Criteria:

In order to participate you must meet the following criteria:

  • Have histologically or cytologically proven diagnosis of adenocarcinoma of the prostate.
  • Have an intact prostate.
  • Have received no more than 28 weeks of standard systemic therapy (SST).

This is a partial list of eligibility requirements.

Study Details

Clinical Trial Investigator

Srinivas Vourganti, MD

Contact Information

Rush Cancer Center Clinical Trials Office


RUSH University Medical Center

1620 W Harrison St
Chicago, IL 60612

Get Directions

Clinical Trial FAQs

Find out if a clinical trial makes sense for you.

Learn more
Learn more